LINJARDY 5mg/25mg Tablets 14s:
LINJARDY 5mg/25mg Tablets 14s – Dual Action Therapy for Type 2 Diabetes Management
LINJARDY Tablets combine Empagliflozin 25mg (an SGLT2 inhibitor) and Linagliptin 5mg (a DPP-4 inhibitor), providing a powerful and complementary treatment for adults with Type 2 Diabetes Mellitus. This dual oral therapy helps control blood glucose levels through multiple pathways, improving both fasting and postprandial glucose while offering added cardiovascular and renal benefits.
Key Features:
-
Combines Empagliflozin 25mg + Linagliptin 5mg
-
Targets both insulin-independent and insulin-dependent pathways
-
Helps reduce HbA1c, fasting, and post-meal blood sugar
-
Provides added benefits for heart and kidney health
-
Once-daily oral tablet for easy compliance
-
Pack Size: 14 tablets
Indications:
-
Type 2 Diabetes Mellitus in adults
-
Patients not adequately controlled with diet, exercise, and monotherapy
-
Especially suitable for patients with cardiovascular risk or mild renal dysfunction
How It Works:
-
Empagliflozin blocks SGLT2 in the kidneys, increasing glucose excretion in urine and lowering blood glucose levels.
-
Linagliptin increases incretin hormone levels (GLP-1, GIP), boosting insulin secretion and suppressing glucagon release.
Benefits:
-
Dual mechanism for better glycemic control
-
Helps with weight loss and blood pressure reduction
-
Low risk of hypoglycemia
-
Cardiovascular and renal protective effects (empagliflozin component)
Dosage & Administration:
-
One tablet once daily, with or without food
-
Use as prescribed by your physician based on individual clinical needs
Precautions:
-
Not for use in Type 1 diabetes or diabetic ketoacidosis
-
Monitor kidney function and stay hydrated
-
May cause increased urination, genital infections, or mild GI upset
-
Use with caution in patients with renal or hepatic impairment
Storage:
-
Store below 30°C in a dry place
-
Keep out of reach of children